JP2005529934A - キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス - Google Patents

キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス Download PDF

Info

Publication number
JP2005529934A
JP2005529934A JP2004509683A JP2004509683A JP2005529934A JP 2005529934 A JP2005529934 A JP 2005529934A JP 2004509683 A JP2004509683 A JP 2004509683A JP 2004509683 A JP2004509683 A JP 2004509683A JP 2005529934 A JP2005529934 A JP 2005529934A
Authority
JP
Japan
Prior art keywords
compound
group
alkyl
cycloalkyl
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004509683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529934A5 (https=
Inventor
ビラス エイチ． ダハヌカー，
ホア エヌ． グェン，
セシリア エー． オール，
フチェン ザン，
イリア エー． ザビアラブ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005529934A publication Critical patent/JP2005529934A/ja
Publication of JP2005529934A5 publication Critical patent/JP2005529934A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2004509683A 2002-05-31 2003-05-30 キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス Pending JP2005529934A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38447802P 2002-05-31 2002-05-31
PCT/US2003/017042 WO2003101992A1 (en) 2002-05-31 2003-05-30 Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Publications (2)

Publication Number Publication Date
JP2005529934A true JP2005529934A (ja) 2005-10-06
JP2005529934A5 JP2005529934A5 (https=) 2006-07-06

Family

ID=29712039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004509683A Pending JP2005529934A (ja) 2002-05-31 2003-05-30 キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス

Country Status (16)

Country Link
US (2) US7074923B2 (https=)
EP (1) EP1509525B9 (https=)
JP (1) JP2005529934A (https=)
CN (2) CN101538224A (https=)
AR (1) AR040232A1 (https=)
AT (1) ATE336494T1 (https=)
AU (1) AU2003238822A1 (https=)
CA (1) CA2483923A1 (https=)
CY (1) CY1105774T1 (https=)
DE (1) DE60307628T2 (https=)
DK (1) DK1509525T5 (https=)
ES (1) ES2270047T3 (https=)
MX (1) MXPA04011862A (https=)
PT (1) PT1509525E (https=)
WO (1) WO2003101992A1 (https=)
ZA (1) ZA200408719B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1368349B1 (de) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
JP2005529933A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビター多形体
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) * 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
WO2005012303A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP2010500326A (ja) * 2006-08-08 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) * 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
JPH0374369A (ja) * 1989-06-01 1991-03-28 Merck & Co Inc アンギトテンシン２拮抗剤
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH09510983A (ja) * 1994-04-05 1997-11-04 ヘキスト・アクチエンゲゼルシヤフト 好酸球の顆粒球の病理学的な過剰反応性を減少するためのキサンチン誘導体の使用、新規なキサンチン化合物およびそれらの製法
JPH1059969A (ja) * 1996-06-07 1998-03-03 Hoechst Ag ショック状態の治療および予防用のテオフィリン誘導体の使用、新規キサンチン化合物およびその製造方法
WO2002024698A1 (en) * 2000-09-19 2002-03-28 Schering Corporation Xanthine phosphodiesterase v inhibitors
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
CA2030112A1 (en) * 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
NZ238609A (en) * 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
JPH04279586A (ja) * 1991-03-05 1992-10-05 Hokuriku Seiyaku Co Ltd キサンチン誘導体
EP0538194B1 (de) * 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE19540798A1 (de) 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
AU2001268958B2 (en) * 2000-07-04 2006-03-09 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
EP1368349B1 (de) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ATE395349T1 (de) * 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
AU2002331311A1 (en) * 2001-09-19 2003-04-01 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
AU2003201274A1 (en) * 2002-01-11 2003-07-24 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
JP2005529933A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビター多形体
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
ES2339112T3 (es) * 2002-08-21 2010-05-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos.
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AU2003280680A1 (en) * 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
WO2005012303A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0374369A (ja) * 1989-06-01 1991-03-28 Merck & Co Inc アンギトテンシン２拮抗剤
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH09510983A (ja) * 1994-04-05 1997-11-04 ヘキスト・アクチエンゲゼルシヤフト 好酸球の顆粒球の病理学的な過剰反応性を減少するためのキサンチン誘導体の使用、新規なキサンチン化合物およびそれらの製法
JPH1059969A (ja) * 1996-06-07 1998-03-03 Hoechst Ag ショック状態の治療および予防用のテオフィリン誘導体の使用、新規キサンチン化合物およびその製造方法
WO2002024698A1 (en) * 2000-09-19 2002-03-28 Schering Corporation Xanthine phosphodiesterase v inhibitors
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6009061609, ＢＲＩＤＳＯＮ，Ｐ．Ｋ． ｅｔ ａｌ, "Ｓｙｎｔｈｅｓｉｓ ａｎｄ ａｄｅｎｏｓｉｎｅ ｒｅｃｅｐｔｏｒ ａｆｆｉｎｉｔｙ ｏｆ ７−β−Ｄ−ｒｉｂｏｆｕｒａｎｏｓｙｌｘａｎｔｈｉｎｅ", Ｎｕｃｌｅｏｓｉｄｅｓ ＆ Ｎｕｃｌｅｏｔｉｄｅｓ, 1998, Ｖｏｌ．１７， Ｎｏ．４, ｐｐ．７５９−７６８ *
JPN6009061611, ＰＯＮＣＥ，Ｍ．Ａ． ｅｔ ａｌ, "Ｓｙｎｔｈｅｓｉｓ ａｎｄ ｉｓｏｌａｔｉｏｎ ｏｆ ｂｒｏｍｏ−β−ｃａｒｂｏｌｉｎｅｓ ｏｂｔａｉｎｅｄ ｂｙ ｂｒｏｍｉｎａｔｉｏｎ ｏｆ β−ｃａｒｂｏｌｉｎｅ ａｌｋａｌｏｉｄｓ", Ｊｏｕｒｎａｌ ｏｆ Ｈｅｔｅｒｏｃｙｃｌｉｃ Ｃｈｅｍｉｓｔｒｙ, 2001, Ｖｏｌ．３８， Ｎｏ．５, ｐｐ．１０８７−１０９５ *
JPN6009061613, 実験化学講座２０ 第４版, 1992, ｐｐ．１７５−１７９ *
JPN6009061614, ＢＲＩＤＳＯＮ，Ｐ．Ｋ． ｅｔ ａｌ, "１−Ｓｕｂｓｔｉｔｕｔｅｄ ｘａｎｔｈｉｎｅｓ", Ｓｙｎｔｈｅｓｉｓ, 1995, Ｎｏ．７, ｐｐ．８５５−８５８ *

Also Published As

Publication number Publication date
CA2483923A1 (en) 2003-12-11
CN100497336C (zh) 2009-06-10
AR040232A1 (es) 2005-03-23
MXPA04011862A (es) 2005-03-31
CN101538224A (zh) 2009-09-23
ES2270047T3 (es) 2007-04-01
PT1509525E (pt) 2006-12-29
ZA200408719B (en) 2005-11-15
EP1509525A1 (en) 2005-03-02
DE60307628D1 (de) 2006-09-28
US7786301B2 (en) 2010-08-31
WO2003101992A1 (en) 2003-12-11
EP1509525B9 (en) 2007-10-31
DK1509525T3 (da) 2006-12-11
US7074923B2 (en) 2006-07-11
HK1068139A1 (en) 2005-04-22
AU2003238822A1 (en) 2003-12-19
DK1509525T5 (da) 2007-07-30
US20060205943A1 (en) 2006-09-14
EP1509525B1 (en) 2006-08-16
ATE336494T1 (de) 2006-09-15
DE60307628T2 (de) 2007-08-09
CN1668618A (zh) 2005-09-14
US20030232987A1 (en) 2003-12-18
CY1105774T1 (el) 2011-02-02

Similar Documents

Publication Publication Date Title
JP2005529934A (ja) キサンチンホスホジエステラーゼｖインヒビターおよびその前駆物質を調製するプロセス
EP2190804B1 (en) Process and intermediates for preparing integrase inhibitors
JP5817079B2 (ja) ６−（７−（（１−アミノシクロプロピル）メトキシ）−６−メトキシキノリン−４−イルオキシ）−ｎ−メチル−１−ナフトアミド、またはそれの薬学的に許容される塩を調製するための方法
KR20130004393A (ko) 인테그라제 억제제의 제조를 위한 방법 및 중간체
JPWO1996032366A1 (ja) ナフトール誘導体およびその製法
JP3378315B2 (ja) カルバゾロン誘導体及びその調製方法
SE447479B (sv) Forfarande for selektiv framstellning av isosorbid-5-nitrat
AU2008313425B2 (en) Improved process for preparing 2-(substituted phenyl)-2-hydroxy-ethyl carbamates
EP1719772A1 (en) Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
US7223871B2 (en) Process for preparing substituted imidazole derivatives and intermediates used in the process
HK1097547A (en) Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
HK1068139B (en) Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
EP0273321A1 (en) 7-Bromo-beta-carboline compound and method for producing same
JP2726653B2 (ja) ジアミノピリミジン誘導体
EP2217585A2 (en) Process for the preparation of 2h-chromene-3-carbamate derivatives
EP0254611B1 (fr) Dérivés 8-phénylthiotétrahydroquinoléines substitués et leurs sels, leur préparation à titre de médicaments et les compositions les renfermant
EP0269841B1 (fr) 1-Hydroxyalkylxanthines, leurs procédés de préparation et médicament les contenant
JPH06279414A (ja) アリールヒダントインの製造方法
JPH0339072B2 (https=)
BE897358A (fr) Derives amines de benzylidene-pyrrolo [2,1-b] quinazolines et de benzylidene-pyrido [2,1-b] quinazolines
HU204771B (en) Process for producing anilinofumarates from chloromaleates or chlorofumarates or from their mixture
MC1276A1 (fr) Derives d'uree basiques substitues et procede pour leur preparation
JPH1180076A (ja) ２，３，４−トリフルオロ−５−ヨ−ド安息香酸、そのエステル類及びその製造法
GB2104508A (en) Improved process for the preparation of 2,4,-diamino-5-(3',4',5'-trimethoxy-benzyl) pyrimidine
HK1141785B (en) Process and intermediates for preparing integrase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100524